Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.33 |
| ▸ | HTR3B | O95264 | 2/20 | 0.33 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720688 | 0.76 | HTR3A (0.42) | HTR2CHTR2ASLC6A4HTR3EHTR3B | |
| SCHEMBL4318925 | 0.75 | HTR3A (0.49) | HTR2CHTR2ASLC6A4HTR3EHTR3B | |
| SCHEMBL4313251 | 0.73 | SLC6A2 (0.36) | HTR2CHTR2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4660475 | 0.71 | SLC6A2 (0.37) | SLC6A4SLC6A2SLC6A3PIM1 | |
| SCHEMBL5829529 | 0.71 | CHRNB2 (0.45) | HTR2CHTR2ASLC6A4HTR3EHTR3B | |
| SCHEMBL5492496 | 0.70 | RECQL (0.35) | PKMKDM4EALDH1A1 | |
| SCHEMBL3650828 | 0.70 | HTR6 (0.58) | HTR2AHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4719880 | 0.70 | HTR3E (0.33) | HTR2CHTR2ASLC6A4HTR3EHTR3B | |
| SCHEMBL532873 | 0.70 | NPC1 (0.50) | SLC6A4SLC6A2SLC6A3PRMT5HTR3E | |
| SCHEMBL844937 | 0.70 | KDM4E (0.59) | HTR2CSLC6A4PRMT5HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1534292-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1578429-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1511745-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7109233-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1532115-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050256105-A1 | Cysteine protease and serine protease inhibitors; arthritis, parasite infections, osteoporosis, gingivitis; e.g. benzofuran-2-carboxylic acid [(S)-1-((S)-1-cyclohexylmethyl-3,7-dioxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide | JEONG JAE U | 2005-11-17 | — | — | US | disclosed |
| US-20050256100-A1 | Protease inhibitors | JEONG JAE U | 2005-11-17 | — | — | US | disclosed |
| WO-2005034838-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-1511492-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1511745-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
| WO-2003103574-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104257-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003099844-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003097593-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | HTR2C 4034/4885HTR2A 3891/4885SLC6A4 3780/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | HTR2C 3921/4885HTR2A 3995/4885SLC6A4 3642/4885 |
| US-20050256100-A1 | Protease inhibitors | SPINT2, PRSS1, ADAM17 | HTR2C 3125/4885HTR2A 3446/4885SLC6A4 4156/4885 |
| US-20050256105-A1 | Cysteine protease and serine protease inhibitors; arthritis, parasite infections, osteoporosis, gingivitis; e.g. benzofuran-2-carboxylic acid [(S)-1-((S)-1-cyclohexylmethyl-3,7-dioxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide | PRSS1, SPINT2, CTRL | HTR2C 2122/4885HTR2A 3183/4885SLC6A4 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.